The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZ.
Zou J, et al. Among authors: hecht d.
J Mol Med (Berl). 2020 Aug;98(8):1161-1173. doi: 10.1007/s00109-020-01943-6. Epub 2020 Jul 6.
J Mol Med (Berl). 2020.
PMID: 32632752
Free PMC article.